Pyrethroid and organophosphate insecticide exposure in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease: An immunohistochemical analysis of tyrosine hydroxylase and glial fibrillary acidic protein in dorsolateral striatum

Toxicology and Industrial Health

Volumn 25, Issue 1, 2009, Pages 25-39

  Dodd, Ca ^a   Klein, Bg ^a  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

Author keywords

avidin biotin histochemistry; C57BL 6; caudate putamen; chlorpyrifos; permethrin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CHLORPYRIFOS; GLIAL FIBRILLARY ACIDIC PROTEIN; PERMETHRIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; ENVIRONMENTAL EXPOSURE; EXPERIMENTAL MODEL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUROPATHOLOGY; NEUROPIL; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PUTAMEN;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CHLORPYRIFOS; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; DRUG INTERACTIONS; GLIAL FIBRILLARY ACIDIC PROTEIN; INSECTICIDES; MICE; MICE, INBRED C57BL; NEOSTRIATUM; NEUROPIL; PARKINSONIAN DISORDERS; PERMETHRIN; TYROSINE 3-MONOOXYGENASE;

EID: 63549148493     PISSN: 07482337     EISSN: None     Source Type: Journal    
DOI: 10.1177/0748233709102752     Document Type: Article

References (56)

1. Ahmad M (2004) Potentiation/antagonism of deltamethrin and cypermethrins with organophosphate insecticides in the cotton bollworm, Helicovera armigera (Lepidoptera: Noctuidae). Pestic Biochem Physiol 80: 31–42.
2. Ahmad M (2007) Potentiation/antagonism of pyrethroids with organophosphate insecticides in Bemisia tabaci (Homoptera: Aleyrodidae). J Econ Entomol 100: 886–893.
3. Becquet D, Girardet C, Guillaumond F, Francois-Belland A-M, Bosler O (2008) Ultrastructural plasticity in the rat suprachiasmatic nucleus. Possible involvement in clock entrainment. Glia 56: 294–305.
4. Bloomquist JR, Barlow RL, Gillette JS, Li W, Kirby ML (2002) Selective effects of insecticides on nigrostriatal dopaminergic nerve pathways. Neurotoxicology 23: 537–544.
5. Bushnell PJ, Pope CN, Padilla S (1993) Behavioral and neurochemical effects of acute chlorpyrifos in rats: tolerance to prolonged inhibition of cholinesterase. J Pharmacol Exp Ther 266: 1007–1017.
6. Cragg SJ (2006) Meaningful silences: how dopamine listens to the ACh pause. Trends Neurosci 29: 125–131.
7. Croisier E, Graeber MB (2006) Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration. Acta Neuropathol 112: 517–530.
8. Date I, Felten DL, Felten SY (1990) Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. Brain Res 519: 266–276.
9. Dervan AG, Meshul CK, Beales M, McBean GJ, Moore C, Totterdell S (2004) Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease. Exp Neurol 190: 145–156.
10. Dhillon AS, Tarbutton GL, Levin JL, Plotkin GM, Lowry LK, Nalbone JT (2008) Pesticide/environmental exposures and Parkinson's disease in East Texas. J Agromedicine 13: 37–48.
11. Doherty JD, Morii N, Hiromori T, Ohnishi J (1988) Pyrethroids and the striatal dopaminergic system in vivo. Comp Biochem Physiol C 91: 371–375.
12. Elwan MA, Richardson JR, Guillot TS, Caudle WM, Miller GW (2006) Pyrethroid pesticide-induced alterations in dopamine transporter function. Toxicol Appl Pharmacol 211: 188–197.
13. Franklin KBJ, Paxinos GP (1997) The Mouse Brain in Sterotaxic Coordinates. San Diego, CA: Academic Press.
14. Frigerio R, Sanft KR, Grossardt BR, Peterson BJ, Elbaz A, Bower JH (2006) Chemical exposures and Parkinson's disease: a population-based case-control study. Mov Disord 21: 1688–1692.
15. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ (1998) The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50: 1346–1350.
16. Graybiel AM, Hirsch EC, Agid Y (1990) The nigrostriatal system in Parkinson's disease. Adv Neurol 53: 17–29.
17. Himeda T, Watanabe Y, Tounai H, Hayakawa N, Kato H, Araki T (2006) Time dependent alterations of co-localization of S100beta and GFAP in the MPTP-treated mice. J Neural Transm 113: 1887–1894.
18. Hirsch EC, Hoglinger G, Rousselet E, Breidert T, Parain K, Feger J (2003) Animal models of Parkinson's disease in rodents induced by toxins: an update. J Neural Transm 65(Suppl.): 89–100.
19. Hodaie M, Neimat JS, Lozano AM (2007) The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies. Neurosurgery 60: 17–28.
20. Hu Z, Cooper M, Crockett DP, Zhou R (2004) Differentiation of the midbrain dopaminergic pathways during mouse development. J Comp Neurol 476: 301–311.
21. Jonsson G, Mefford I, Olson L, Stromberg I, Sundstrom E, Hoffer B (1986) Electrophysiological and neurochemical correlates of the neurotoxic effects of MPTP on central catecholamine neurons in the mouse. In: SP Markey, N Castagnoli, AJ Trevor, IJ Kopin (eds), MPTP: A Neurotoxin Producing a Parkinsonian Syndrome. Orlando, FL: Academic Press, pp. 275–288.
22. Kamel F, Tanner C, Umbach D, Hoppin J, Alavanja M, Blair A (2007) Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. Am J Epidemiol 165: 364–374.
23. Karanth S, Liu J, Mirajkar N, Pope C (2006) Effects of acute chlorpyrifos exposure on in vivo acetylcholine accumulation in rat striatum. Toxicol Appl Pharmacol 216: 150–156.
24. Karanth S, Pope C (2003) Age-related effects of chlorpyrifos and parathion on acetylcholine synthesis in rat striatum. Neurotoxicol Teratol 25: 599–606.
25. Karen DJ, Li W, Harp PR, Gillette JS, Bloomquist JR (2001) Striatal dopaminergic pathways as a target for the insecticides permethrin and chlorpyrifos. Neurotoxicology 22: 811–817.
26. Kirby ML, Barlow RL, Bloomquist JR (2002) Selective effects of cyclodiene insecticides on dopamine release in mammalian synaptosomes. Toxicol Appl Pharmacol 181: 89–92.
27. Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318: 876–880.
28. Kou J, Bloomquist JR (2007) Neurotoxicity in murine striatal dopaminergic pathways following long-term application of low doses of permethrin and MPTP. Toxicol Lett 171: 154–161.
29. Kou J, Gillette JS, Bloomquist JR (2006) Neurotoxicity in murine striatal dopaminergic pathways following co-application of permethrin, chlorpyrifos, and MPTP. Pestic Biochem Physiol 85: 68–75.
30. Kurosaki R, Muramatsu Y, Kato H, Araki T (2004) Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson's disease. Pharmacol Biochem Behav 78: 143–153.
31. Laloux C, Derambure P, Kreisler A, Houdayer E, Bruezière S, Bordet R (2008) MPTP-treated mice: long-lasting loss of nigral TH-ir neurons but not paradoxical sleep alterations. Exp Brain Res 186: 635–642.
32. Li AA, Mink PJ, McIntosh LJ, Teta MJ, Finley B (2005) Evaluation of epidemiologic and animal data associating pesticides with Parkinson's disease. J Occup Environ Med 47: 1059–1087.
33. Liu GP, Shi N, Liang JH, Chen L (2004) Effects of pyrethroids on dopamine and its metabolites in nigrostriatum of male rats. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 22: 368–370.
34. Liu J, Pope CN (1998) Comparative presynaptic neurochemical changes in rat striatum following exposure to chlorpyrifos or parathion. J Toxicol Environ Health A 53: 531–544.
35. Miller RJ, Wing J, Cope SE, Klavons JA, Kline DL (2004) Repellency of permethrin-treated battle-dress uniforms during Operation Tandem Thrust 2001. J Am Mosq Control Assoc 20: 462–464.
36. Misra BR, Klein BG (1995) Functional properties of cells in rat trigeminal subnucleus interpolaris following local serotonergic deafferentation. Somatosens Mot Res 12: 11–28.
37. Moratalla R, Quinn B, DeLanney LE, Irwin I, Langston JW, Graybiel AM (1992) Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A 89: 3859–3863.
38. O'Callaghan JP, Sriram K (2005) Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. Expert Opin Drug Saf 4: 433–442.
39. Olsen CH (2003) Review of the use of statistics in infection and immunity. Infect Immun 71: 6689–6692.
40. Pekny M, Nilsson M (2005) Astrocyte activation and reactive gliosis. Glia 50: 427–434.
41. Pittman JT, Dodd CA, Klein BG (2003) Immunohistochemical changes in the mouse striatum induced by the pyrethroid insecticide permethrin. Int J Toxicol 22: 359–370.
42. Przedborski S, Vila M (2003) The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 991: 189–198.
43. Reynolds AD, Kadiu I, Garg SK, Glanzer JG, Nordgren T, Ciborowski P (2008) Nitrated alpha-synuclein and microglial neuroregulatory activities. J Neuroimmune Pharmacol 3: 59–74.
44. Richardson JR, Caudle WM, Guillot TS, Watson JL, Nakamaru-Ogiso E, Seo BB (2007) Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Sci 95: 196–204.
45. Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, Collins AC (2004) Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol 65: 1526–1535.
46. Seniuk NA, Tatton WG, Greenwood CE (1990) Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res 527: 7–20.
47. Sherer TB, Kim JH, Betarbet R, Greenamyre JT (2003) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 179: 9–16.
48. Sidhu A, Wersinger C, Vernier P (2004) Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J 18: 637–647.
49. Snow BJ, Vingerhoets FJ, Langston JW, Tetrud JW, Sossi V, Calne DB (2000) Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J Neurol Neurosurg Psychiatry 68: 313–316.
50. Soderlund DM, Clark JM, Sheets LP, Mullin LS, Piccirillo VJ, Sargent D (2002) Mechanisms of pyrethroid neurotoxicity: implications for cumulative risk assessment. Toxicology 171: 3–59.
51. Steiner B, Winter C, Hosman K, Siebert E, Kempermann G, Petrus DS (2006) Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson's disease. Exp Neurol 199: 291–300.
52. Takada M, Li ZK, Hattori T (1990) Astroglial ablation prevents MPTP-induced nigrostriatal neuronal death. Brain Res 509: 55–61.
53. Watanabe H, Muramatsu Y, Kurosaki R, Michimata M, Matsubara M, Imai Y (2004) Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study. Eur Neuropsychopharmacol 14: 93–104.
54. Webster RA (2001) Neurotransmitters, Drugs and Brain Function. Chichester, UK: John Wiley and Sons.
55. Whitton PS (2007) Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 150: 963–976.
56. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19: 533–542.